Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Andreas K Øvlisen
  • Lasse H Jakobsen
  • Sandra Eloranta
  • Kristian H Kragholm
  • Martin Hutchings
  • Henrik Frederiksen
  • Peter Kamper
  • Rasmus Bo Dahl-Sørensen
  • Danny Stoltenberg
  • Caroline E Weibull
  • Joshua P Entrop
  • Ingrid Glimelius
  • Karin E Smedby
  • Christian Torp-Pedersen
  • Marianne T Severinsen
  • Tarec C El-Galaly
View graph of relations

PURPOSE: The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care.

MATERIALS AND METHODS: All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use.

RESULTS: A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators.

CONCLUSION: The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options.

Original languageEnglish
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume39
Issue number31
Pages (from-to)3463-3472
Number of pages10
ISSN0732-183X
DOIs
Publication statusPublished - 1 Nov 2021

ID: 68135155